Publication|Articles|November 19, 2026

Pharmacy Practice in Focus: Health Systems

  • November 2026
  • Volume 15
  • Issue 6

Rebuilding Vaccine Confidence: A Pharmacist’s Field Guide

Fact checked by: Yasmeen Qahwash
Listen
0:00 / 0:00

Key Takeaways

  • Declining childhood immunization rates are enabling outbreaks, underscoring the need to restore MMR coverage above ~95% to mitigate measles transmission risk.
  • Adult and pediatric vaccines reliably reduce severe disease, hospitalization, and mortality, while serious adverse events remain uncommon and typically outweighed by infection-associated risks.
SHOW MORE

In every practice setting, pharmacists can meet vaccine hesitancy with evidence, effective communication, and vetted resources that move patients toward “yes.”

About the Authors

Lindsey Griggs, PharmD, is a clinical assistant professor at the University of Missouri-Kansas City School of Pharmacy and an infectious diseases–trained acute care clinical pharmacist practitioner at Harry S. Truman Memorial Veterans’ Hospital in Columbia, Missouri.

Tina Zheng, PharmD, BCIDP, is a clinical pharmacotherapy specialist in infectious diseases and antimicrobial stewardship at NYU Langone Health in New York, New York.

Patricia Saunders-Hao, PharmD, BCIDP, BCPS (AQ-ID), is a senior clinical pharmacy specialist in infectious diseases at North Shore University Hospital in Manhasset, New York, and a site coordinator for the Long Island Jewish Medical Center and North Shore University Hospital PGY2 Infectious Diseases Pharmacy Residency program in New Hyde Park, New York.

Introduction

Vaccines have the potential to prevent disease, hospitalization, and death. A 2024 US report noted that routine childhood vaccinations had prevented more than 500 million cases of illness, 30 million hospitalizations, and
1 million deaths in children born between 1994 and 2023.1 However, childhood vaccination rates are declining worldwide, leading to outbreaks of vaccine-preventable diseases such as measles. In the US, vaccination rates of the measles, mumps, and rubella (MMR) vaccine have fallen in many states, often below the 95% threshold.2

One major driver of decreased immunizations is vaccine hesitancy. The World Health Organization defines vaccine hesitancy as a “delay in acceptance or refusal of safe vaccines despite availability of vaccination services” and listed it in the top 10 global health threats in 2019.3,4 There can be various reasons for vaccine hesitancy, including misinformation and lack of understanding, fear of potential adverse effects (AEs), religious and cultural beliefs, and mistrust in government and in the pharmaceutical industry.5 Understanding and addressing the cause of an individual’s vaccine hesitancy is paramount in combating this issue.

Pharmacists are among the most trusted and accessible health professionals, giving them an opportunity to address vaccine hesitancy. Across every setting, they can rebuild vaccine confidence by combining fluency in evidence, effective conversations, and vetted resources.

The Evidence Base for Vaccinations

Patients encounter vaccine claims constantly, often without context. Pharmacists can build confidence by explaining that vaccines may not prevent every infection but consistently reduce severe illness, hospitalization, and death (Tables 1 and 2).

In adults, influenza, COVID-19, pneumococcal conjugate, and respiratory syncytial virus (RSV) vaccines reduce severe respiratory outcomes such as hospitalization and death. Serious AEs are uncommon. Some effects like myocarditis and pericarditis were observed with pre-2022 COVID-19 vaccination in adolescent and young adult male patients, though these risks were mitigated with a longer dosing interval. Guillain-Barré syndrome is a rare warning for some respiratory vaccines, including RSV, but the benefit-risk balance remains favorable.

In children, influenza, COVID-19, pneumococcal conjugate, and MMR vaccines prevent severe illness and its complications. Maternal RSV vaccination at 32 to 36 weeks’ gestation also reduces infant RSV illness and hospitalization. Serious AEs are uncommon, although certain vaccines carry a small increased risk of febrile seizures or immune thrombocytopenia.

Concerns about vaccine safety include persistent claims that vaccines cause autism. The controversy linking MMR vaccination to autism began with a 1998 case series of 12 children that relied on retrospective parental reports to suggest an association. The report was subsequently retracted, and large epidemiologic studies have found no causal relationship between MMR vaccination and autism.6 Although rare AEs (eg, febrile seizures) can occur, the risks associated with vaccine-preventable infections are greater.

A simple summary pharmacists can share with patients is the following: “No vaccine is completely risk-free, but serious reactions are rare, and vaccination helps prevent the complications we worry about most.”

Effective Conversations: What to Say and How to Say It

Start with a presumptive recommendation and emphasize the social norm.15,16 Treat the vaccine as the expected next step, not an open question. “You’re due for your flu shot today” lands very differently than “Would you like to receive a flu shot?” One assumes yes, whereas the other invites conversation. In one observational study, approximately 74% of parents agreed to vaccinate their children when clinicians used a presumptive opener vs 4% with a participatory approach.16 A confident recommendation from a trusted professional remains a strong predictor of uptake.18 Pharmacists can also note that most people choose to vaccinate: “More than 90% of my patients get this annually.”

Utilize motivational interviewing (MI) when encountering resistance. Ask permission before sharing facts, use open-ended questions, and reflect the patient’s concern rather than overriding it.16 In one MI-based trial, human papillomavirus vaccine series initiation rose by an absolute 9.4 percentage points vs controls, with lower hesitancy scores still measurable months later.19 Rather than reciting a generic script, directly address the patient’s concern by matching your response to the actual worry (eg, safety, necessity, “too many at once”).16,20

Bundle all due vaccines.21 Recommend everything indicated in one conversation. For most combinations, same-day coadministration at separate sites is safe and improves series completion (HR of 1.45 for bundled first doses).22 A few vaccines require spacing, so use clinical judgment, but make coadministration the default when appropriate.

Close by removing barriers.23 Offer to administer the vaccine(s) now (a walk-in, same-day receipt) to spare the patient a separate trip. When that isn’t possible, a simple reminder still pays off: Reminders alone raise uptake by approximately 28%.24 The easier you make it, the more likely a patient is to follow through.

Online Table 1. Resources for All Settings Stratified by Need

Need

Resource(s)

Staying Informed

Social Media Accounts to Follow

Instagram:

  • @WHO
  • @IDSAInfo
  • @SIDPharm
  • @the_aafp
  • @ImmunizeOrg
  • @CDCgov

X (Twitter):

  • @WHO
  • @IDSAInfo
  • @SIDPharm
  • @PediatricsAAP
  • @aafp
  • @VaccinesToday
  • @ImmunizeOrg
  • @CDCgov

Email Subscriptions

  • IZ Express (Immunize.org) – free weekly immunization newsletter
  • CDC and AAP e-mail alerts — sign-ups available on their respective sites to receive new recommendations as released

Clinical Decision-Making

See Online Table 2 for population-specific vaccine schedules.

Mobile Apps

CDC’s “Vaccine Schedules”

CDC’s “PneumoRecs VaxAdvisor”

Specific examples are described in Table 3. Even the best conversation needs backup. Online Tables 1 and 2 provide resources organized by practical needs across practice settings and by patient population. With the evidence, the communication, and these resources in hand, the rest is follow-through.

Conclusion

Disclosures

The authors have nothing to disclose.

This article was reviewed by Society of Infectious Diseases Pharmacists committee members Stuart Greaser, PharmD, BCIDP; and Isabelle Lim, PharmD.

Pharmacists are among the most accessible and trusted sources of vaccine information. By pairing a confident, evidence-based recommendation with effective communication and credible resources, pharmacists can help patients move from uncertainty to informed action. A patient’s decision to decline vaccination today should be viewed as “not yet,” not a closed door. Address the concern, offer vaccination at the point of care when possible, and revisit the conversation at future encounters. Each respectful discussion is an opportunity to protect an individual patient, their family, and the broader community.

REFERENCES
  1. Zhou F, Jatlaoui TC, Leidner AJ, et al. Health and economic benefits of routine childhood immunizations in the era of the Vaccines for Children Program - United States, 1994-2023. MMWR Morb Mortal Wkly Rep. 2024;73(31):682-685. doi:10.15585/mmwr.mm7331a2
  2. Maintain the vaccination coverage level of 2 doses of the MMR vaccine for children in kindergarten — IID-04. Healthy People 2030. Accessed October 7, 2026. https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination/maintain-vaccination-coverage-level-2-doses-mmr-vaccine-children-kindergarten-iid-04
  3. Summary WHO SAGE Conclusions and Recommendations on Vaccine Hesitancy. World Health Organization; 2015. Accessed October 9, 2026. https://www.who.int/docs/default-source/immunization/demand/summary-of-sage-vaccinehesitancy-en.pdf
  4. Ten threats to global health in 2019. World Health Organization. Accessed September 25, 2026. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
  5. Brumbaugh KQ, Gellert F, Mokdad AH. Understanding vaccine hesitancy: insights and improvement strategies drawn from a multi-study review. Vaccines (Basel). 2025;13(10):1003. doi:10.3390/vaccines13101003
  6. Institute of Medicine (US) Immunization Safety Review Committee. Immunization Safety Review: Vaccines and Autism. Washington (DC): National Academies Press (US); 2004. doi:10.17226/10997
  7. Senerth E, Sheikholeslamian SM, Sivakumaran K, et al. Influenza vaccine effectiveness and safety for the 2026-2027 respiratory season. JAMA. Published online September 2, 2026. doi:10.1001/jama.2026.18126
  8. Lipson RA, Senerth E, Watson MA, et al. COVID-19 vaccine effectiveness and safety for the 2026-2027 respiratory season. JAMA. Published online September 2, 2026. doi:10.1001/jama.2026.18191
  9. Senerth E, Sheikholeslamian SM, Babatunde I, et al. RSV immunization effectiveness and safety for the 2026-2027 respiratory season. JAMA. Published online September 2, 2026. doi:10.1001/jama.2026.17871
  10. Farrar JL, Childs L, Ouattara M, et al. Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults. Pathogens. 2023;12(5):732. doi:10.3390/pathogens12050732
  11. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-1125. doi:10.1056/NEJMoa1408544
  12. Hajdu G, Hughes T, Ouedraogo GL, et al. Safety of a 4-dose 20-valent pneumococcal conjugate vaccine series in infants: a randomized trial. Pediatrics. 2024;154(5):e2023065218. doi:10.1542/peds.2023-065218
  13. Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics. 2009;123(6):e1103-e1110. doi:10.1542/peds.2008-3422
  14. Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2021;11(11):CD004407. doi:10.1002/14651858.CD004407.pub5
  15. Robinson JD, Opel DJ. Word choice and the patient encounter. JAMA. 2024;332(15):1296-1297. doi:10.1001/jama.2024.15857
  16. O'Leary ST. Strategies for communicating with parents about vaccines. JAMA. 2025;333(24):2197-2198. doi:10.1001/jama.2025.4882
  17. Opel DJ, Heritage J, Taylor JA, et al. The architecture of provider-parent vaccine discussions at health supervision visits. Pediatrics. 2013;132(6):1037-1046. doi:10.1542/peds.2013-2037
  18. Malik AA, Ahmed N, Shafiq M, et al. Behavioral interventions for vaccination uptake: a systematic review and meta-analysis. Health Policy. 2023;137:104894. doi:10.1016/j.healthpol.2023.104894
  19. Ramalli L, Cogordan C, Fressard L, et al. Sustained impact of motivational interviewing on reducing vaccine hesitancy among postpartum mothers: a randomized control trial, Southeastern France, 2021 to 2022. Hum Vaccin Immunother. 2026;22(1):2611647. doi:10.1080/21645515.2025.2611647
  20. Cannity KM. Therapist disclosure to combat COVID-19 vaccine hesitancy: a narrative review. J Behav Med. 2023;46(1-2):346-355. doi:10.1007/s10865-022-00305-6
  21. Bonanni P, Steffen R, Schelling J, et al. Vaccine co-administration in adults: an effective way to improve vaccination coverage. Hum Vaccin Immunother. 2023;19(1):2195786. doi:10.1080/21645515.2023.2195786
  22. Zhu Y, Wu CF, Giuliano AR, et al. Tdap-HPV vaccination bundling in the USA: trends, predictors, and implications for vaccine series completion. Prev Med. 2022;164:107218. doi:10.1016/j.ypmed.2022.107218
  23. Omer SB, Benjamin RM, Brewer NT, et al. Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet. 2021;398(10317):2186-2192. doi:10.1016/S0140-6736(21)02507-1
  24. Jacobson Vann JC, Jacobson RM, Coyne-Beasley T, Asafu-Adjei JK, Szilagyi PG. Patient reminder and recall interventions to improve immunization rates. Cochrane Database Syst Rev. 2018;1(1):CD003941. doi:10.1002/14651858.CD003941.pub3

Related to this article